NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
Clinical Trials
13 trialsNCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT05156892 2025-05-15
TICTOC
St Vincent's Hospital, Sydney
Phase 1 Active not recruiting
NCT04961632 2024-02-01
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
National Cancer Centre, Singapore
Phase 1 Unknown
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02936206 2021-05-19
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT01192308 2020-12-01
KINETAM
Radboud University Medical Center
Phase 1 Completed
NCT02513849 2017-05-09
Tamoxifen in Patients With Oesophageal Cancer
University of Nottingham
Phase 1 Unknown
NCT00005886 2017-01-13
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
University of Kansas Medical Center
Phase 1 Completed
NCT00009997 2011-03-28
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NYU Langone Health
Phase 1 Completed
NCT00003080 2010-09-15
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00005822 2010-06-11
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Case Comprehensive Cancer Center
Phase 1 Completed